Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (958.750 €): Dynamisches Zusammenspiel von DNA-Methylierung, Histonmodifikationen und Super-Enhancer-Aktivität in normalen T-Zellen und bei bösartiger T-Zelltransformation Hor 18.06.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Dynamisches Zusammenspiel von DNA-Methylierung, Histonmodifikationen und Super-Enhancer-Aktivität in normalen T-Zellen und bei bösartiger T-Zelltransformation
Dynamic interplay between histone modifications and DNA methylation defines the chromatin structure of the humane genome and serves as a conceptual framework to understand transcriptional regulation in normal development and human disease. The ultimate goal of this research proposal is to study the chromatin architecture during normal and malignant T cell differentiation in order to define how DNA methylation drives oncogenic gene expression as a novel concept in cancer research. T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of pediatric and 25% of adult ALL cases and was originally identified as a highly aggressive tumor entity. T-ALL therapy has been intensified leading to gradual improvements in survival. However, 20% of pediatric and 50% of adult T-ALL cases still relapse and ultimately die because of refractory disease. Research efforts have unravelled the complex genetic basis of T-ALL but failed to identify new promising targets for precision therapy. Recent studies have identified a subset of T-ALLs whose transcriptional programs resemble those of early T-cell progenitors (ETPs), myeloid precursors and hematopoietic stem cells. Importantly, these so-called ETP-ALLs are characterized by early treatment failure and an extremely poor prognosis. The unique ETP-ALL gene expression signature suggests that the epigenomic landscape in ETP-ALL is markedly different as compared to other genetic subtypes of human T-ALL. My project aims to identify genome-wide patterns of DNA methylation and histone modifications in genetic subtypes of human T-ALL as a basis for elucidating how DNA methylation drives the expression of critical oncogenes in the context of poor prognostic ETP-ALL. Given that these ETP-ALL patients completely fail current chemotherapy treatment, tackling this completely novel aspect of ETP-ALL genetics will yield new targets for therapeutic intervention in this aggressive haematological malignancy.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Universiteit Gent | 958.750 € |
Quelle: https://cordis.europa.eu/project/id/639784
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Universiteit Gent Andere Rechtsform, 9000 Gand, Belgien.